Acute Myeloid Leukaemia Therapeutics Market is worth USD 3.8 Billion in 2023 and is estimated to grow at a CAGR of 12.15% in the forecast period. The forecast revenue hints at a growth of around 9.12 billion USD by 2030. The Acute Myeloid Leukaemia Therapeutics Market is witnessing significant growth propelled by notable factors. Advancements in medical technology and the increasing demand for effective AML treatments are driving market expansion. The market is characterized by the development of targeted therapies, immunotherapies, and supportive care medications aimed at enhancing patient outcomes. Personalized medicine approaches, including molecular diagnostics and genetic profiling, are instrumental in identifying novel therapeutic targets and enabling tailored treatment strategies. Robust research and development endeavours, clinical trials, and collaborations between pharmaceutical firms and academic institutions are fostering innovation within the Acute Myeloid Leukaemia Therapeutics Market.To know about the Research Methodology :- Request Free Sample Report
Acute Myeloid Leukaemia Market Drivers:
The Acute Myeloid Leukaemia Therapeutics Market is experiencing significant growth driven by factors such as the rising incidence of AML cases, advancements in medical technology, and strategic collaborations between pharmaceutical companies and academic institutions. The market presents lucrative business opportunities for stakeholders as they focus on developing targeted and personalized therapies to meet the unmet medical needs of AML patients. Investments in research and development activities are paving the way for innovative drugs and treatment approaches, while the utilization of molecular diagnostics and genetic profiling enhances treatment precision. Overall, the market holds promise for both improved patient outcomes and substantial business growth. Acute Myeloid Leukaemia Market Challenges: The Acute Myeloid Leukaemia Therapeutics Market encounters challenges in addressing the complexity of the disease, high development costs, drug resistance, competition, patient access, and clinical trial complexities. The heterogeneous nature of AML necessitates personalized treatment approaches, while the high costs and stringent regulations hinder the development of innovative therapies. Drug resistance and intense competition further complicate treatment options, and ensuring patient access to therapies globally remains a challenge. Additionally, the complexities of clinical trials and patient recruitment pose obstacles in advancing AML therapeutics. Overcoming these challenges requires ongoing research, collaboration, and innovation in the market. Acute Myeloid Leukaemia Market Trends: These trends in the Acute Myeloid Leukaemia Therapeutics Market reflect a dynamic landscape that is constantly evolving to meet the challenges posed by the disease. As researchers and pharmaceutical companies delve deeper into understanding the molecular intricacies of AML, the development of targeted and personalized therapies holds great promise in achieving more precise and effective treatment outcomes. With the integration of innovative approaches, collaborative partnerships, and the utilization of real-world evidence, the Acute Myeloid Leukaemia Therapeutics Market is poised to make significant strides in improving patient care and advancing the field of AML treatment.
Acute Myeloid Leukaemia Market Segmentation:
Type: In the Acute Myeloid Leukaemia Therapeutics Market, targeted therapies have emerged as a prominent segment, offering personalized treatment approaches by specifically targeting genetic mutations and molecular abnormalities in AML cells. This segment is driven by the increasing understanding of the genetic basis of AML and the development of innovative targeted drugs. Chemotherapy remains a widely adopted treatment type, providing a standard approach for inducing remission in AML patients. Drug Class: Hypomethylating agents hold a significant market share in the Acute Myeloid Leukaemia Therapeutics Market, with drugs like azacytidine and decitabine being widely used. These agents have shown efficacy in reversing abnormal DNA methylation patterns in AML cells, offering potential treatment options for patients. Kinase inhibitors are also gaining traction as a promising drug class, targeting specific kinase enzymes involved in the growth and survival of AML cells.Distribution Channel: Hospitals play a crucial role in the distribution of AML therapeutics, providing comprehensive treatment facilities and specialized medical expertise. Specialty clinics focusing on haematology and oncology offer tailored treatment options for AML patients, leveraging their specialized knowledge and resources. Additionally, retail pharmacies serve as convenient access points for AML medications, ensuring accessibility for patients in community settings. The rise of online pharmacies has further expanded distribution channels, offering the convenience of home delivery and accessibility for patients. Region: The North American region dominates the Acute Myeloid Leukaemia Therapeutics Market, driven by leading pharmaceutical companies and advanced healthcare infrastructure. Europe also holds a significant market share, with countries like Germany, France, and the United Kingdom contributing to market growth. The Asia Pacific region is witnessing rapid growth, attributed to the increasing prevalence of AML, improving healthcare infrastructure, and rising investments in research and development. Latin America and the Middle East & Africa regions are emerging markets, experiencing a growing demand for AML therapeutics and witnessing improvements in access to healthcare and treatment options. Competitive Landscape: The competitive landscape of the Acute Myeloid Leukaemia Market is characterized by the presence of several manufacturers and brands vying for a share in the market. Key players in the market continuously strive to innovate and differentiate their offerings to gain a competitive edge. Established manufacturers in the Acute Myeloid Leukaemia market include Pfizer Inc., Novartis AG, Celgene Corporation.
Acute Myeloid Leukaemia Therapeutics Market Scope: Inquire before buying
Global Acute Myeloid Leukaemia Therapeutics Market Report Coverage Details Base Year: 2023 Forecast Period: 2024-2030 Historical Data: 2018 to 2023 Market Size in 2023: US $ 3.8 Bn. Forecast Period 2024 to 2030 CAGR: 12.15% Market Size in 2030: US $ 9.12 Bn. Segments Covered: by Disease Type Myeloblastic Promyelocytic Myelomonocytic by Treatment Class Chemotherapy Targeted Therapy Immunotherapy Hypomethylating Agents Others by Distribution channel Hospitals Specialty Clinics Retail Pharmacies Online Pharmacies Acute Myeloid Leukaemia Therapeutics Market, by Region
North America (United States, Canada and Mexico) Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe) Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC) Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A) South America (Brazil, Argentina Rest of South America)Acute Myeloid Leukaemia Therapeutics Market,Key Players:
1. Pfizer Inc. 2. Novartis AG 3. Celgene Corporation (Acquired by Bristol Myers Squibb) 4. Astellas Pharma Inc. 5. Daiichi Sankyo Company, Limited 6. Jazz Pharmaceuticals 7. AbbVie Inc. 8. Boehringer Ingelheim International GmbH 9. Johnson & Johnson 10. Gilead Sciences, Inc. 11. Amgen Inc. 12. Takeda Pharmaceutical Company Limited 13. Merck & Co., Inc. 14. Sunesis Pharmaceuticals, Inc. 15. Agios Pharmaceuticals, Inc. FAQ Q.1) What is the CAGR of Acute Myeloid Leukaemia Market? Ans: The CAGR for Acute Myeloid Leukaemia Market is 12.15% Q.2) Which are the leading companies in Acute Myeloid Leukaemia Market? Ans: Pfizer Inc., Novartis AG and Celgene Corporation. are some of the leading companies in the Acute Myeloid Leukaemia Market Q.3) Which region shows maximum potential in Acute Myeloid Leukaemia Market Ans: North America is expected to grow exponentially and is likely to dominate Acute Myeloid Leukaemia Market in future. Q,4) Which is the leading region in Acute Myeloid Leukaemia Market? Ans: Asia Pacific leads the market of Acute Myeloid Leukaemia Market significantly Q.5) What was the forecasted period of this report? Ans: The forecasted period for the Acute Myeloid Leukaemia Market research was 2024 – 2030
1. Acute Myeloid Leukaemia Therapeutics Market Introduction 1.1. Study Assumption and Market Definition 1.2. Scope of the Study 1.3. Executive Summary 2. Acute Myeloid Leukaemia Therapeutics Market: Dynamics 2.1. Acute Myeloid Leukaemia Therapeutics Market Trends by Region 2.1.1. North America Acute Myeloid Leukaemia Therapeutics Market Trends 2.1.2. Europe Acute Myeloid Leukaemia Therapeutics Market Trends 2.1.3. Asia Pacific Acute Myeloid Leukaemia Therapeutics Market Trends 2.1.4. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Trends 2.1.5. South America Acute Myeloid Leukaemia Therapeutics Market Trends 2.2. Acute Myeloid Leukaemia Therapeutics Market Dynamics by Region 2.2.1. North America 2.2.1.1. North America Acute Myeloid Leukaemia Therapeutics Market Drivers 2.2.1.2. North America Acute Myeloid Leukaemia Therapeutics Market Restraints 2.2.1.3. North America Acute Myeloid Leukaemia Therapeutics Market Opportunities 2.2.1.4. North America Acute Myeloid Leukaemia Therapeutics Market Challenges 2.2.2. Europe 2.2.2.1. Europe Acute Myeloid Leukaemia Therapeutics Market Drivers 2.2.2.2. Europe Acute Myeloid Leukaemia Therapeutics Market Restraints 2.2.2.3. Europe Acute Myeloid Leukaemia Therapeutics Market Opportunities 2.2.2.4. Europe Acute Myeloid Leukaemia Therapeutics Market Challenges 2.2.3. Asia Pacific 2.2.3.1. Asia Pacific Acute Myeloid Leukaemia Therapeutics Market Drivers 2.2.3.2. Asia Pacific Acute Myeloid Leukaemia Therapeutics Market Restraints 2.2.3.3. Asia Pacific Acute Myeloid Leukaemia Therapeutics Market Opportunities 2.2.3.4. Asia Pacific Acute Myeloid Leukaemia Therapeutics Market Challenges 2.2.4. Middle East and Africa 2.2.4.1. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Drivers 2.2.4.2. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Restraints 2.2.4.3. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Opportunities 2.2.4.4. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Challenges 2.2.5. South America 2.2.5.1. South America Acute Myeloid Leukaemia Therapeutics Market Drivers 2.2.5.2. South America Acute Myeloid Leukaemia Therapeutics Market Restraints 2.2.5.3. South America Acute Myeloid Leukaemia Therapeutics Market Opportunities 2.2.5.4. South America Acute Myeloid Leukaemia Therapeutics Market Challenges 2.3. PORTER’s Five Forces Analysis 2.4. PESTLE Analysis 2.5. Technology Roadmap 2.6. Regulatory Landscape by Region 2.6.1. North America 2.6.2. Europe 2.6.3. Asia Pacific 2.6.4. Middle East and Africa 2.6.5. South America 2.7. Key Opinion Leader Analysis For Acute Myeloid Leukaemia Therapeutics Industry 2.8. Analysis of Government Schemes and Initiatives For Acute Myeloid Leukaemia Therapeutics Industry 2.9. Acute Myeloid Leukaemia Therapeutics Market Trade Analysis 2.10. The Global Pandemic Impact on Acute Myeloid Leukaemia Therapeutics Market 3. Acute Myeloid Leukaemia Therapeutics Market: Global Market Size and Forecast by Segmentation by Demand and Supply Side (by Value in USD Million) 2023-2030 3.1. Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 3.1.1. Myeloblastic 3.1.2. Promyelocytic 3.1.3. Myelomonocytic 3.2. Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 3.2.1. Chemotherapy 3.2.2. Targeted Therapy 3.2.3. Immunotherapy 3.2.4. Hypomethylating Agents 3.2.5. Others 3.3. Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 3.3.1. Hospitals 3.3.2. Specialty Clinics 3.3.3. Retail Pharmacies 3.3.4. Online Pharmacies 3.4. Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Region (2023-2030) 3.4.1. North America 3.4.2. Europe 3.4.3. Asia Pacific 3.4.4. Middle East and Africa 3.4.5. South America 4. North America Acute Myeloid Leukaemia Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 4.1. North America Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 4.1.1. Myeloblastic 4.1.2. Promyelocytic 4.1.3. Myelomonocytic 4.2. North America Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 4.2.1. Chemotherapy 4.2.2. Targeted Therapy 4.2.3. Immunotherapy 4.2.4. Hypomethylating Agents 4.2.5. Others 4.3. North America Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 4.3.1. Hospitals 4.3.2. Specialty Clinics 4.3.3. Retail Pharmacies 4.3.4. Online Pharmacies 4.4. North America Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Country (2023-2030) 4.4.1. United States 4.4.1.1. United States Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 4.4.1.1.1. Myeloblastic 4.4.1.1.2. Promyelocytic 4.4.1.1.3. Myelomonocytic 4.4.1.2. United States Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 4.4.1.2.1. Chemotherapy 4.4.1.2.2. Targeted Therapy 4.4.1.2.3. Immunotherapy 4.4.1.2.4. Hypomethylating Agents 4.4.1.2.5. Others 4.4.1.3. United States Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 4.4.1.3.1. Hospitals 4.4.1.3.2. Specialty Clinics 4.4.1.3.3. Retail Pharmacies 4.4.1.3.4. Online Pharmacies 4.4.2. Canada 4.4.2.1. Canada Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 4.4.2.1.1. Myeloblastic 4.4.2.1.2. Promyelocytic 4.4.2.1.3. Myelomonocytic 4.4.2.2. Canada Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 4.4.2.2.1. Chemotherapy 4.4.2.2.2. Targeted Therapy 4.4.2.2.3. Immunotherapy 4.4.2.2.4. Hypomethylating Agents 4.4.2.2.5. Others 4.4.2.3. Canada Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 4.4.2.3.1. Hospitals 4.4.2.3.2. Specialty Clinics 4.4.2.3.3. Retail Pharmacies 4.4.2.3.4. Online Pharmacies 4.4.3. Mexico 4.4.3.1. Mexico Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 4.4.3.1.1. Myeloblastic 4.4.3.1.2. Promyelocytic 4.4.3.1.3. Myelomonocytic 4.4.3.2. Mexico Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 4.4.3.2.1. Chemotherapy 4.4.3.2.2. Targeted Therapy 4.4.3.2.3. Immunotherapy 4.4.3.2.4. Hypomethylating Agents 4.4.3.2.5. Others 4.4.3.3. Mexico Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 4.4.3.3.1. Hospitals 4.4.3.3.2. Specialty Clinics 4.4.3.3.3. Retail Pharmacies 4.4.3.3.4. Online Pharmacies 5. Europe Acute Myeloid Leukaemia Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 5.1. Europe Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 5.2. Europe Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 5.3. Europe Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 5.4. Europe Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Country (2023-2030) 5.4.1. United Kingdom 5.4.1.1. United Kingdom Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 5.4.1.2. United Kingdom Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 5.4.1.3. United Kingdom Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.2. France 5.4.2.1. France Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 5.4.2.2. France Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 5.4.2.3. France Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.3. Germany 5.4.3.1. Germany Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 5.4.3.2. Germany Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 5.4.3.3. Germany Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.4. Italy 5.4.4.1. Italy Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 5.4.4.2. Italy Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 5.4.4.3. Italy Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.5. Spain 5.4.5.1. Spain Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 5.4.5.2. Spain Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 5.4.5.3. Spain Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.6. Sweden 5.4.6.1. Sweden Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 5.4.6.2. Sweden Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 5.4.6.3. Sweden Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.7. Austria 5.4.7.1. Austria Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 5.4.7.2. Austria Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 5.4.7.3. Austria Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 5.4.8. Rest of Europe 5.4.8.1. Rest of Europe Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 5.4.8.2. Rest of Europe Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 5.4.8.3. Rest of Europe Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6. Asia Pacific Acute Myeloid Leukaemia Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 6.1. Asia Pacific Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 6.2. Asia Pacific Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 6.3. Asia Pacific Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4. Asia Pacific Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Country (2023-2030) 6.4.1. China 6.4.1.1. China Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 6.4.1.2. China Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 6.4.1.3. China Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.2. S Korea 6.4.2.1. S Korea Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 6.4.2.2. S Korea Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 6.4.2.3. S Korea Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.3. Japan 6.4.3.1. Japan Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 6.4.3.2. Japan Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 6.4.3.3. Japan Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.4. India 6.4.4.1. India Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 6.4.4.2. India Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 6.4.4.3. India Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.5. Australia 6.4.5.1. Australia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 6.4.5.2. Australia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 6.4.5.3. Australia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.6. Indonesia 6.4.6.1. Indonesia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 6.4.6.2. Indonesia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 6.4.6.3. Indonesia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.7. Malaysia 6.4.7.1. Malaysia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 6.4.7.2. Malaysia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 6.4.7.3. Malaysia Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.8. Vietnam 6.4.8.1. Vietnam Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 6.4.8.2. Vietnam Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 6.4.8.3. Vietnam Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.9. Taiwan 6.4.9.1. Taiwan Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 6.4.9.2. Taiwan Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 6.4.9.3. Taiwan Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 6.4.10. Rest of Asia Pacific 6.4.10.1. Rest of Asia Pacific Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 6.4.10.2. Rest of Asia Pacific Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 6.4.10.3. Rest of Asia Pacific Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 7. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 7.1. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 7.2. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 7.3. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 7.4. Middle East and Africa Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Country (2023-2030) 7.4.1. South Africa 7.4.1.1. South Africa Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 7.4.1.2. South Africa Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 7.4.1.3. South Africa Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 7.4.2. GCC 7.4.2.1. GCC Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 7.4.2.2. GCC Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 7.4.2.3. GCC Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 7.4.3. Nigeria 7.4.3.1. Nigeria Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 7.4.3.2. Nigeria Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 7.4.3.3. Nigeria Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 7.4.4. Rest of ME&A 7.4.4.1. Rest of ME&A Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 7.4.4.2. Rest of ME&A Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 7.4.4.3. Rest of ME&A Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 8. South America Acute Myeloid Leukaemia Therapeutics Market Size and Forecast by Segmentation (by Value in USD Million) 2023-2030 8.1. South America Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 8.2. South America Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 8.3. South America Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 8.4. South America Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Country (2023-2030) 8.4.1. Brazil 8.4.1.1. Brazil Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 8.4.1.2. Brazil Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 8.4.1.3. Brazil Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 8.4.2. Argentina 8.4.2.1. Argentina Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 8.4.2.2. Argentina Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 8.4.2.3. Argentina Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 8.4.3. Rest Of South America 8.4.3.1. Rest Of South America Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Disease Type (2023-2030) 8.4.3.2. Rest Of South America Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Treatment Class (2023-2030) 8.4.3.3. Rest Of South America Acute Myeloid Leukaemia Therapeutics Market Size and Forecast, by Distribution Channel (2023-2030) 9. Global Acute Myeloid Leukaemia Therapeutics Market: Competitive Landscape 9.1. MMR Competition Matrix 9.2. Competitive Landscape 9.3. Key Players Benchmarking 9.3.1. Company Name 9.3.2. Business Segment 9.3.3. End-user Segment 9.3.4. Revenue (2022) 9.3.5. Company Locations 9.4. Leading Acute Myeloid Leukaemia Therapeutics Market Companies, by market capitalization 9.5. Market Structure 9.5.1. Market Leaders 9.5.2. Market Followers 9.5.3. Emerging Players 9.6. Mergers and Acquisitions Details 10. Company Profile: Key Players 10.1. Pfizer Inc. 10.1.1. Company Overview 10.1.2. Business Portfolio 10.1.3. Financial Overview 10.1.4. SWOT Analysis 10.1.5. Strategic Analysis 10.1.6. Scale of Operation (small, medium, and large) 10.1.7. Details on Partnership 10.1.8. Regulatory Accreditations and Certifications Received by Them 10.1.9. Awards Received by the Firm 10.1.10. Recent Developments 10.2. Novartis AG 10.3. Celgene Corporation (Acquired by Bristol Myers Squibb) 10.4. Astellas Pharma Inc. 10.5. Daiichi Sankyo Company, Limited 10.6. Jazz Pharmaceuticals 10.7. AbbVie Inc. 10.8. Boehringer Ingelheim International GmbH 10.9. Johnson & Johnson 10.10. Gilead Sciences, Inc. 10.11. Amgen Inc. 10.12. Takeda Pharmaceutical Company Limited 10.13. Merck & Co., Inc. 10.14. Sunesis Pharmaceuticals, Inc. 10.15. Agios Pharmaceuticals, Inc. 11. Key Findings 12. Industry Recommendations 13. Acute Myeloid Leukaemia Therapeutics Market: Research Methodology 14. Terms and Glossary